摘要
近年来,多项研究显示细胞周期蛋白依赖性激酶4和6(CDK4/6)抑制剂对于激素受体阳性晚期乳腺癌患者具有较好的疗效,甚至可改善内分泌耐药问题。相关研究表明CDK4/6抑制剂联合内分泌治疗在临床应用中极具前景。
Recently,cyclin-dependent kinase 4 and 6（CDK4/6） inhibitors are identified to be useful in breast cancer patients with positive estrogen receptor,and could improve the efficacy of endocrine therapy against HR ＋ breast cancer. The ongoing studies confirm the benefits and tolerability of CDK 4/6 inhibition,and the combination therapy with endocrine agents may become a new standard for breast cancer.
出处
《肿瘤学杂志》
CAS
2017年第9期807-811,共5页
Journal of Chinese Oncology
基金
国家自然科学基金(81372407)
湖北省自然基金(2014CFB394)
湖北省卫计委项目(WJ2017M027)
